To examine whether contrast-enhanced ultrasound (CEUS) parameters in patients with advanced pancreatic cancer could be used to assess response to treatment with pulsed-wave high intensity focused ultrasound (PW-HIFU).
METHODS:
We prospectively recorded the pretreatment and posttreatment CEUS related parameters, CA19-9, pain scores of 30 patients with advanced pancreatic cancer treated with PW-HIFU treatment. Correlation of clinical parameters, tumor characteristics, and PW-HIFU treatment energy with CEUS parameters were analyzed.
RESULTS:
Pain score decreased after treatment (from 4.80±2.14 to 3.28±1.93, p = 0.001). CA19-9 dropped in RT decreased group, 4 weeks after one session PW-HIFU, compared with prolonged group (p = 0.013). According to the display of blood vessels in the mass by CEUS, tumors were classified by vessel grade (VG), VG1: no vessel can be seen; VG 2: vessels diameter < 5 mm; VG 3: vessels diameter > 5 mm. VGs were different between increased and decreased relative rise intensity (rRI) groups (p = 0.008). VG1 group shown a decreased rRI after treatment, while VG3 group showed the opposite trend (p = 0.006).
CONCLUSIONS:
CEUS can evaluating response to PW-HIFU in advanced pancreatic cancer. Quantitative analysis may help to assess the short-term efficacy of patients and help for individualized treatment.
DababouS, MarrocchioC, ScipioneR, et al. High-Intensity Focused Ultrasound for Pain Management in Patients with Cancer. Radiographics. 2018;38:603–23.
3.
DababouS, MarrocchioC, RosenbergJ, et al. A meta-analysis of palliative treatment of pancreatic cancer with high intensity focused ultrasound. J Ther Ultrasound. 2017;5:9.
4.
ChenY, GaoSG, ChenJM, et al. Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients. Cell Biochem Biophys. 2015;71:1287–91.
5.
BallehaninnaUK, ChamberlainRS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105–19.
6.
MarinovaM, HuxoldHC, HenselerJ, et al. Clinical Effectiveness and Potential Survival Benefit of US-Guided High-Intensity Focused Ultrasound Therapy in Patients with Advanced-Stage Pancreatic Cancer. Ultraschall Med. 2019;40:625–37.
7.
JiY, ZhangY, ZhuJ, et al. Response of patients with locally advanced pancreatic adenocarcinoma to high-intensity focused ultrasound treatment: a single-center, prospective, case series in China. Cancer Manag Res. 2018;10:4439–46.
8.
ThudiumM, BetteB, TongucT, et al. Multidisciplinary management and outcome in pancreatic cancer patients treated with high-intensity focused ultrasound. Int J Hyperthermia. 2020;37:456–62.
9.
van der ZeeJ. Heating the patient: a promising approach?Ann Oncol. 2002;13:1173–84.
10.
WustP, HildebrandtB, SreenivasaG, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3:487–97.
11.
LiT, WangYN, KhokhlovaTD, et al. Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer. Cancer Res. 2015;75:3738–46.
12.
LeeES, LeeJY, KimH, et al. Pulsed high-intensity focused ultrasound enhances apoptosis of pancreatic cancer xenograft with gemcitabine. Ultrasound Med Biol. 2013;39:1991–2000.
13.
WuF. High intensity focused ultrasound: a noninvasive therapy for locally advanced pancreatic cancer. World J Gastroenterol. 2014;20:16480–8.
14.
WernerJM, ZidekM, KammererS, et al. Intraoperative contrast-enhanced ultrasound can have a crucial role in surgical decision-making during hepato-pancreatico-biliary surgery - Analysis of impact and input. Clin Hemorheol Microcirc. 2021;78:103–16.
15.
SidhuPS, CantisaniV, DietrichCF, et al. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). Ultraschall Med. 2018;39:e2–e44.
16.
ZhangQ, WuL, YangD, et al. Clinical application of dynamic contrast enhanced ultrasound in monitoring the treatment response of chemoradiotherapy of pancreatic ductal adenocarcinoma. Clin Hemorheol Microcirc. 2020;75:325–34.
17.
WeiY, SongS, DuanN, et al. MT1-MMP-Activated Liposomes to Improve Tumor Blood Perfusion and Drug Delivery for Enhanced Pancreatic Cancer Therapy. Adv Sci (Weinh). 2020;7:1902746.
18.
TemperoMA, MalafaMP, ChioreanEG, et al. Pancreatic Adenocarcinoma, Version 1. J Natl Compr Canc Netw. 2019;17:202–10.
19.
ZhaoJ, ShenH, HuX, WangY, YuanY. The efficacy of a new high-intensity focused ultrasound therapy for metastatic pancreatic cancer. Int J Hyperthermia. 2021;38:288–95.
20.
NarayananG, DayeD, WilsonNM, et al. Ablation in Pancreatic Cancer: Past, Present and Future. Cancers (Basel). 2021;13.
21.
QiuB, ZhangX, TsauoJ, et al. Transcatheter arterial infusion for pancreatic cancer: a 10-year National Cancer Center experience in 115 patients and literature review. Abdom Radiol (NY). 2019;44:2801–8.
22.
JungEM, EngelM, WiggermannP, et al. Contrast enhanced ultrasound (CEUS) with parametric imaging after irreversible electroporation (IRE) of the prostate to assess the success of prostate cancer treatment. Clin Hemorheol Microcirc. 2021;77:303–10.
23.
JangHJ, LeeJY, LeeDH, KimWH, HwangJH. Current and Future Clinical Applications of High-Intensity Focused Ultrasound (HIFU) for Pancreatic Cancer. Gut Liver. 2010;4(Suppl 1):S57–61.
24.
JiCL, LiXL, HeYP, et al. Quantitative parameters of contrast-enhanced ultrasound in breast invasive ductal carcinoma: The correlation with pathological prognostic factors. Clin Hemorheol Microcirc. 2017;66:333–45.
25.
TeraoT, KumagiT, HyodoI, et al. Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. Medicine (Baltimore). 2021;100:e27591.
26.
WhatcottCJ, DiepCH, JiangP, et al. Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer. Clin Cancer Res. 2015;21:3561–8.
27.
ProvenzanoPP, CuevasC, ChangAE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418–29.
28.
ChenIM, WillumsenN, DehlendorffC, et al. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. Int J Cancer. 2020;146:2913–22.
29.
KoliosMC, SherarMD, HuntJW. Blood flow cooling and ultrasonic lesion formation. Med Phys. 1996;23:1287–98.
30.
van BreugelJMM, de GreefM, WijlemansJW, et al. Thermal ablation of a confluent lesion in the porcine kidney with a clinically available MR-HIFU system. Phys Med Biol. 2017;62:5312–26.
31.
LortonO, GuilleminP, HolmanR, et al. Enhancement of HIFU thermal therapy in perfused tissue models using micron-sized FTAC-stabilized PFOB-core endovascular sonosensitizers. Int J Hyperthermia. 2020;37:1116–30.
32.
NeesseA, MichlP, FreseKK, et al. Stromal biology and therapy in pancreatic cancer. Gut. 2011;60:861–8.
33.
StylianopoulosT, MartinJD, SnuderlM, et al. Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse. Cancer Res. 2013;73:3833–41.
34.
OliveKP, JacobetzMA, DavidsonCJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457–61.
35.
KimH, MorganDE, SchexnailderP, et al. Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Point-of-Care Perfusion Phantom: A Pilot Study. Invest Radiol. 2019;54:16–22.
36.
SofuniA, ItoiT, ItokawaF, et al. Usefulness of contrast-enhanced ultrasonography in determining treatment efficacy and outcome after pancreatic cancer chemotherapy. World J Gastroenterol. 2008;14:7183–91.
